Bordetella pertussis adhesins and toxins

Bordetella pertussis adhesins and toxins are a group of specialized virulence factors produced by the bacterium Bordetella pertussis, the causative agent of whooping cough. Key adhesins—such as filamentous hemagglutinin (FHA), fimbriae (FIM2, FIM3), and pertactin (PRN)—mediate attachment to ciliated respiratory epithelial cells, initiating colonization. The principal toxins—pertussis toxin (PT; an AB5-family ADP-ribosyltransferase), adenylate cyclase-hemolysin (ACT; elevates intracellular cAMP), and tracheal cytotoxin (TCT; causes ciliated cell damage)—disrupt host defenses and cellular functions, promote inflammation, and facilitate persistent infection. The production of these factors is regulated by the BvgA/BvgS two-component regulatory system. Some adhesins and toxins interact or function redundantly in promoting colonization or immune evasion. Current acellular pertussis vaccines utilize purified forms of key adhesins and toxins (PT, FHA, PRN, FIM) to induce protective immunity. Because “Bordetella pertussis adhesins and toxins” refers to a class of molecules, not a specific therapeutic target, future structured entries should represent each adhesin or toxin separately as an individual protein or enzyme.

Other names

B. pertussis virulence factorsB. pertussis adhesins (FHA, fimbriae/FIM, pertactin/PRN)B. pertussis toxins (pertussis toxin/PT, adenylate cyclase-hemolysin/ACT, tracheal cytotoxin/TCT)Filamentous hemagglutinin (FHA)Pertussis toxin (PT)Pertactin (PRN)Adenylate cyclase-hemolysin (ACT)Tracheal cytotoxin (TCT)

Vaccines: Induce antibody-mediated immunity against key adhesins and toxins (PT, FHA, PRN, FIM), neutralizing virulence. Antibiotics: Inhibit bacterial growth/survival, reducing production of adhesins and toxins indirectly. Direct pharmacological inhibition of toxins/adhesins is experimental and not established clinically.